Evaluation of the Protective Effect of Beta Glucan on Amikacin Ototoxicity Using Distortion Product Otoacoustic Emission Measurements in Rats.
- Author:
Tuba BAYINDIR
1
;
Aliye FILIZ
;
Mustafa IRAZ
;
Serdar KAYA
;
Mehmet TAN
;
Mahmut Tayyar KALCIOGLU
Author Information
1. Department of Otorhinolaryngology, Inonu University Medical Faculty, Malatya, Turkey.
- Publication Type:Original Article
- Keywords:
Beta glucan;
Amikacin;
Otoacoustic emission measurement
- MeSH:
Amikacin;
Animals;
beta-Glucans;
Hearing;
Hearing Loss;
Rats
- From:Clinical and Experimental Otorhinolaryngology
2013;6(1):1-6
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: This experimental study investigated the possible protective effect of beta glucans on amikacin ototoxicity. METHODS: Thirty-eight rats with normal distortion product otoacoustic emissions (DPOAEs) were divided into four groups. Group K was the control group. Group A was injected intramuscularly (i.m.) with amikacin 600 mg/kg/day between days 1-15. Group AB was given beta glucan gavage 1 mg/kg/day on days 0-15 and given amikacin 600 mg/kg/day i.m. on days 1-15. Group B was administered only beta glucan gavage, 1 mg/kg/day, on days 0-15. The DPOAEs were elicited in different frequency regions between 2,003 and 9,515 Hz, as distortion product diagrams (DPgrams), before and after the medication was administered, in all groups, on days 1, 5, 10, and 15. RESULTS: No significant changes in the DPgrams were observed in group K. In group A, significant deterioration was observed at the 8,003 and 9,515 Hz frequencies on day 10, and at the 3,991, 4,557, 5,660, 6,726, 8,003, and 9,515 Hz frequencies on day 15. For group AB, statistically significant deterioration was observed at the 2,824, 8,003, and 9,515 Hz frequencies on day 15. The results for group B showed a significant improvement of hearing at the 2,378, 2,824, 3,363, and 3,991 Hz frequencies on day 1, at the 3,363, 3,991, and 8,003 Hz frequencies on day 10, and at the 8,003 Hz frequency on day 15. CONCLUSION: This study suggests that amikacin-induced hearing loss in rats may be limited to some extent by concomitant use of beta glucan.
